Emergent BioSolutions
Emergent BioSolutions' revenue fell 28.8% to $743 million in fiscal 2025. Its operating margin was 13.5%, up from −10.4% a year earlier. Free cash flow was $157 million, up 338.0%. It paid out $25 million in dividends and buybacks, 16% of free cash flow. The diluted share count rose 7.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Emergent BioSolutions does
Emergent BioSolutions sells products that respond to public health threats such as chemical, biological, radiological and nuclear attacks, emerging infectious diseases and drug overdose emergencies. It sells to governments, mainly the U.S. government, and to retail pharmacies.
It has three segments. The Commercial Product segment sells NARCAN and KLOXXADO, nasal sprays that reverse opioid overdoses. NARCAN is sold over the counter at retail pharmacies. The medical countermeasures (MCM) segment includes anthrax and smallpox products, as well as products for diseases such as mpox and Ebola. The Services segment is its contract development and manufacturing business, which it calls Bioservices.
The company earns revenue from selling its products, from its bioservices work for outside customers and from contract and grant funding for research. It says the revenue from its products is a substantial part of its total. It reports a portfolio of 11 products.
Its biggest risks, as it describes them
- A substantial part of its revenue depends on U.S. government purchases, which need ongoing funding decisions.
- It may not win new government contracts when current ones expire.
- Failing to keep its manufacturing sites in compliance could damage its reputation and business.
- Its biologic products must be shipped within set temperature ranges, or product can be lost.
Income statement
From fiscal 2016 to 2025, earnings per share fell 2.1% a year and net income grew 0.2% a year, as new shares raised the share count by 15% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 576 | 643 | 112 | 100 | 205 |
| Debt incl. finance leases | 850 | 1,414 | 868 | 700 | 590 |
| Net debt (negative means net cash) | 274 | 771 | 757 | 600 | 384 |
| Net debt to EBITDA | 0.6x | — | — | 6,005.0x | 2.0x |
| Debt to equity | 0.5x | 1.0x | 1.3x | 1.4x | 1.1x |
| Interest coverage | 9.9x | −4.6x | −8.3x | −1.5x | 1.7x |
| Current ratio | 3.4x | 1.0x | 1.0x | 3.7x | 5.0x |
| Quick ratio | 2.5x | 0.7x | 0.5x | 1.8x | 2.4x |
Cash flow
Projections
Project Emergent BioSolutions' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Emergent BioSolutions shares on the open market, and 6 insiders sold $840,301, $577,200 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | Paul Anthony WilliamsSVP, Products Business | Sold plan | 3,000 | $8.40 | $25,200 | Form 4 |
| May 1, 2026 | Kathryn C ZoonDirector | Sold plan | 17,202 | $8.40 | $144,453 | Form 4 |
| May 1, 2026 | Donald W DeGolyerDirector | Sold plan | 15,481 | $8.40 | $129,994 | Form 4 |
| May 1, 2026 | Sujata Tyagi DayalDirector | Sold plan | 13,761 | $8.40 | $115,610 | Form 4 |
| Apr 30, 2026 | Keith KatkinDirector | Sold plan | 15,481 | $8.28 | $128,183 | Form 4 |
| Apr 1, 2026 | Paul Anthony WilliamsSVP, Products Business | Sold plan | 4,000 | $8.44 | $33,760 | Form 4 |
| Dec 5, 2025 | Ronald RichardDirector | Sold | 21,984 | $11.97 | $263,101 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 6 of 9 | 7 of 9 |
| Rule of 40 | −30.7% | 2.9% | −7.7% |
| Altman Z'' | −2.03 | 1.59 | 3.44 |
| Accruals ratio | −22.2% | −15.5% | −8.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 3 of 9 | 6 of 9 | 7 of 9 |
Compare
Put Emergent BioSolutions side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Emergent BioSolutions | FY25 | −28.8% | 13.5% | 21.1% | 6.4% | 2.0x | 7 | |
| Pacira BioSciences | FY25 | 3.6% | 2.6% | 18.8% | 1.1% | 1.2x | 9 | Compare |
| Corcept Therapeutics | FY25 | 12.8% | 5.9% | 18.6% | 15.7% | −8.1x | 3 | Compare |
| Amphstar Pharmaceuticals | FY25 | −1.6% | 19.5% | 16.8% | 9.9% | 1.7x | 6 | Compare |
| Collegium Pharmaceutical | FY25 | 23.6% | 23.0% | 42.0% | 53.4% | −0.4x | 6 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 489 | 561 | 782 | 1,106 | 1,577 | 1,774 | 1,118 | 1,049 | 1,044 | 743 |
| Revenue growth | −6.5% | 14.8% | 39.5% | 41.4% | 42.6% | 12.4% | −37.0% | −6.1% | −0.5% | −28.8% |
| Gross profit | 362 | 373 | 460 | 672 | 925 | 891 | 383 | 318 | 362 | 417 |
| Research and development | 107 | 97 | 143 | 226 | 238 | 235 | 188 | 111 | 71 | 53 |
| Operating income | 106 | 124 | 90 | 114 | 438 | 341 | −170 | −726 | −109 | 100 |
| Net income | 52 | 83 | 63 | 54 | 306 | 220 | −212 | −760 | −191 | 53 |
| Diluted EPS (US$) | 1.13 | 1.71 | 1.22 | 1.04 | 5.68 | 4.06 | −4.22 | −14.85 | −3.60 | 0.93 |
| Diluted shares (millions) | 49 | 50 | 51 | 52 | 54 | 54 | 50 | 51 | 53 | 57 |
| Cash flow | ||||||||||
| Cash from operations | 55 | 208 | 42 | 188 | 537 | 320 | −34 | −206 | 59 | 171 |
| Capital expenditure | 76 | 55 | 72 | 87 | 142 | 224 | 116 | 52 | 23 | 14 |
| Free cash flow | −22 | 153 | −30 | 101 | 395 | 96 | −150 | −258 | 36 | 157 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 33 | 0 | 0 | 0 | 106 | 82 | 0 | 0 | 25 |
| Acquisitions | 0 | 118 | 828 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 18 | 15 | 23 | 27 | 52 | 42 | 45 | 23 | 18 | 16 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 272 | 178 | 112 | 168 | 621 | 576 | 643 | 112 | 100 | 205 |
| Debt incl. finance leases | 268 | 14 | 809 | 822 | 886 | 850 | 1,414 | 868 | 700 | 590 |
| Total assets | 970 | 1,070 | 2,229 | 2,327 | 2,883 | 2,958 | 3,166 | 1,823 | 1,390 | 1,319 |
| Total liabilities | 374 | 158 | 1,218 | 1,239 | 1,436 | 1,346 | 1,779 | 1,174 | 907 | 796 |
| Shareholders' equity | 596 | 912 | 1,011 | 1,091 | 1,451 | 1,612 | 1,388 | 649 | 483 | 523 |
| Margins and ratios | ||||||||||
| Gross margin | 74.2% | 66.5% | 58.8% | 60.8% | 58.7% | 50.2% | 34.3% | 30.3% | 34.7% | 56.1% |
| Operating margin | 21.6% | 22.2% | 11.5% | 10.3% | 27.8% | 19.2% | −15.2% | −69.2% | −10.4% | 13.5% |
| Net margin | 10.6% | 14.7% | 8.0% | 4.9% | 19.4% | 12.4% | −18.9% | −72.5% | −18.3% | 7.1% |
| Free cash flow margin | −4.4% | 27.3% | −3.9% | 9.1% | 25.0% | 5.4% | −13.4% | −24.6% | 3.4% | 21.1% |
| Rule of 40 (growth + FCF margin) | −10.9% | 42.1% | 35.6% | 50.5% | 67.7% | 17.9% | −50.4% | −30.7% | 2.9% | −7.7% |
| Return on capital | 11.2% | 12.9% | 5.6% | 4.7% | 18.8% | 13.7% | −6.6% | −32.2% | −6.9% | 6.4% |
| Return on equity | 8.2% | 10.9% | 6.5% | 5.2% | 24.1% | 14.3% | −14.1% | −74.7% | −33.7% | 10.5% |
| Return on assets | 5.2% | 8.1% | 3.8% | 2.4% | 11.7% | 7.5% | −6.9% | −30.5% | −11.9% | 3.9% |
| Net debt to EBITDA | −0.0x | −1.1x | 5.5x | 4.0x | 0.5x | 0.6x | — | — | 6,005.0x | 2.0x |